Overview

A Study of BYL719 in Adult Patients With Advanced Solid Malignancies

Status:
Completed
Trial end date:
2015-11-25
Target enrollment:
Participant gender:
Summary
In this study, BYL719 will be administered to adult patients with advanced solid tumors whose disease has progressed despite standard therapy or for whom no standard therapy exists. The trial will investigate the safety and tolerability and determine the MTD of BYL719 in Japanese patients.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals